Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 33.65% year-over-year to $9.6 million, compared with a TTM value of $9.6 million through Dec 2025, down 33.65%, and an annual FY2025 reading of $9.6 million, down 33.65% over the prior year.
  • Other Non-Current Liabilities was $9.6 million for Q4 2025 at Zevra Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $17.5 million in Q2 2025 and bottomed at $14000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $4.5 million, with a median of $369500.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities tumbled 88.43% in 2021, then soared 29732.0% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $31000.0 in 2021, then fell by 19.35% to $25000.0 in 2022, then skyrocketed by 29732.0% to $7.5 million in 2023, then surged by 93.5% to $14.4 million in 2024, then plummeted by 33.65% to $9.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ZVRA at $9.6 million in Q4 2025, $4.0 million in Q3 2025, and $17.5 million in Q2 2025.